secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2021-10-04T23:59:59+00:00
Accession:  0001193125-21-290938
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon promotes Yednock to CIO, hires Mattheakis as CSO
--------------------------------------------------------

- Ted Yednock, formerly CSO since 2013, promoted to Chief Innovation Officer effective immediately.
- Larry Mattheakis appointed Chief Scientific Officer; previously SVP at Protagonist Therapeutics.
- Yednock remains on executive committee, chairs Scientific Advisory Board; focus on C1q platform expansion.
- Mattheakis brings drug discovery experience; company has three clinical-stage candidates in seven trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312521290938/0001193125-21-290938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312521290938/d225159d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-290938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer